J9035 HCPCS code: Injection, bevacizumab, 10 mg
J9035 is the HCPCS Level II code for injection, bevacizumab, 10 mg. In 2024 Medicare paid an average of $53.85 per service for J9035 across 709,756 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 230 per day on outpatient hospital claims. Medicare volume fell 50% from 2022 to 2024 (1,409,411 to 709,756 services). In 2024, about 4,166 clinicians billed Medicare for J9035 for 96,310 beneficiaries; California, Illinois, New York accounted for 25% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2005-01-01 |
| Last action effective | 2005-01-01 |
Who bills J9035 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 4,166 |
| Medicare beneficiaries | 96,310 |
| States with claims | 55 |
| Share of services in top 3 states (California, Illinois, New York) | 25% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9035, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 1,409,411 | 136,662 | $65.60 | $51.61 |
| 2023 | 1,212,819 | 119,290 | $68.69 | $53.97 |
| 2024 | 709,756 | 96,310 | $68.97 | $53.85 |
States with the most J9035 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 76,139 | $46.17 |
| Illinois | 51,601 | $55.44 |
| New York | 50,770 | $51.71 |
| Texas | 45,151 | $56.06 |
| Florida | 42,486 | $56.06 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 230 | CMS Policy |
| practitioner claims | 230 | CMS Policy |
Medicare policy articles for this code
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (458 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C17.0 | Malignant neoplasm of duodenum | 1 |
| C17.1 | Malignant neoplasm of jejunum | 1 |
| C17.2 | Malignant neoplasm of ileum | 1 |
| C17.3 | Meckel's diverticulum, malignant | 1 |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine | 1 |
| C17.9 | Malignant neoplasm of small intestine, unspecified | 1 |
| C18.0 | Malignant neoplasm of cecum | 1 |
| C18.1 | Malignant neoplasm of appendix | 1 |
| C18.2 | Malignant neoplasm of ascending colon | 1 |
| C18.3 | Malignant neoplasm of hepatic flexure | 1 |
Showing 10 of 458. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J9035
- 2005-01-01: J9035 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9035?
J9035 is the HCPCS Level II code for injection, bevacizumab, 10 mg. Short descriptor: "Bevacizumab injection".
How much does Medicare pay for J9035?
In 2024, the average Medicare payment was $53.85 per service (average allowed $68.97).
Does Medicare cover J9035?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J9035?
Medicare policy articles that cite J9035 list 458 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C17.0 (Malignant neoplasm of duodenum), C17.1 (Malignant neoplasm of jejunum), C17.2 (Malignant neoplasm of ileum). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J9035 can be billed per day?
230 on outpatient hospital claims; 230 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9035
- Watch J9035 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9035
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.